For clarification: oral administration of glucocorticoids, which remains prohibited in-competition, includes, in particular, oromucosal, buccal, gingival and sublingual routes
The clinical trial starting dose (1 mg/week) is already close to the community protocol (1.5 mg/week split 3x)
Retatrutide's unique mode of action and versatile therapeutic potential set it apart from many traditional treatment approaches, offering patients new hope and potentially better outcomes
With years of extensive clinical studies proving its positive benefits on Anti-aging, Detoxification, Skin Brightening and Physical performance
Loss of visceral fat around the abdomenthough healthyreduces natural spinal support, potentially increasing load-bearing stress on intervertebral discs and facet joints